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Soluble Fas Ligand: Is It a Critical 
Mediator of Toxic Epidermal 
Necrolysis and Stevens–Johnson 
Syndrome?
Junko Murata1 and Riichiro Abe1
Although soluble Fas ligand (sFasL) is an important candidate in toxic epi-
dermal necrolysis (TEN) and Stevens–Johnson syndrome (SJS), Stur and col-
leagues report that elevated sFasL has been detected in maculopapular 
rashes. In addition to sFasL, other factors, including predisposing genetic fac-
tors, should also be investigated to determine their precise pathogenesis in 
TEN and SJS.
Journal of Investigative Dermatology (2007) 127, 744–745. doi:10.1038/sj.jid.5700693
Toxic epidermal necrolysis (TEN) and 
Stevens–Johnson syndrome (SJS) are 
among the most severe cutaneous 
adverse reactions seen in humans. TEN 
and SJS are life-threatening diseases 
with a mortality rate approaching 25%. 
The main causes of these diseases are 
drug intake and, to a lesser extent, 
viral infection. In TEN and SJS patients’ 
epidermis, marked keratinocyte apop-
totic events are frequently observed. 
This keratinocyte apoptosis results in 
blister formation and widespread skin 
detachment. In contrast to TEN and 
SJS, maculopapular rashes (MPRs) are 
milder variants of cutaneous reac-
tions also due to drug allergy or viral 
infection. Occasional apoptotic kerati-
nocytes are sometimes observed histo-
logically in MPR epidermis.
So far, numerous possible mediators 
of keratinocyte apoptosis have been 
suggested, such as peripheral cytotoxic 
T cells, inflammatory cytokines, nitric 
oxide, granzyme B, and perforin. For 
example, Nassif et al. (2002) showed 
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that T lymphocytes present within TEN 
lesions may exhibit drug-specific cyto-
toxicity against autologous cells with-
out restimulation. However, although 
TEN and SJS lesional skin contained 
few inflammatory cells, there were no 
other convincing ways to explain how 
keratinocyte apoptosis might occur. 
In addition, tumor necrosis factor-α, 
a potent apoptotic mediator, has been 
suggested as a critical factor in TEN and 
SJS (Paquet et al., 1994). As increases 
in serum levels of tumor necrosis fac-
tor-α have been observed in various 
inflammatory diseases, it is unlikely 
that tumor necrosis factor-α alone is a 
specific mediator in TEN and SJS.
In 1998, Viard et al. (1998) reported 
that the activation of Fas through Fas 
ligand (FasL) is an important primary 
step leading to keratinocyte apoptosis 
in TEN. The generally held concept 
is that Fas and FasL are derived from 
keratinocytes, and that FasL expressed 
by keratinocytes causes keratinocyte 
apoptosis in TEN in either an auto-
crine or a paracrine fashion (Viard et 
al., 1998).
Conversely, we demonstrated that 
the levels of soluble FasL (sFasL) in 
patients’ sera were elevated in an ini-
tial phase and significantly declined 
between 3 and 6 days after the start of 
the disease course. We also showed 
that sFasL secretion from peripheral 
blood mononuclear cells could be 
induced after the causative drug stim-
ulation in vitro (Abe et al., 2003).
Clinically, there are some diffi-
culties in diagnosing TEN and SJS. 
Because patients sometimes show 
only maculopapular eruptions without 
any mucosal involvement in the early 
stage of disease, it is quite difficult to 
distinguish TEN and SJS from MPR. It 
is also difficult to determine from a 
patient’s clinical appearance and labo-
ratory data alone whether the disease 
is due to drug intake or viral infection.
Stur and colleagues (2007, this 
issue) show that sFasL levels were 
elevated in sera from SJS patients but 
were low in TEN patients. In addi-
tion to this result, they detected high 
sFasL levels in sera from MPR patients. 
In particular, sFasL serum levels were 
elevated in drug-induced MPR; how-
ever, no significant increase was 
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observed in the patients with viral 
infection. The authors therefore sug-
gest that determination of sFasL serum 
concentration might be useful to dis-
tinguish MPRs caused by drugs versus 
viral infection.
So far it has been assumed that 
high sFasL levels mediated marked 
keratinocyte apoptosis and resulted in 
TEN and SJS. Previous reports demon-
strated that sFasL serum levels in MPR 
patients were not elevated (Abe et al., 
2003). MPR, SJS, and TEN are consid-
ered to be part of the same spectrum 
of diseases, and it was expected that 
sFasL levels might be correlated to the 
severity of these diseases.
Now, important scientific issues 
arise from the data in this paper: If 
serum sFasL levels are elevated in 
MPR patients, what other unknown 
factors might affect disease progress-
ing to TEN and SJS? Furthermore, what 
are the indicators that differentiate 
MPR from TEN and SJS? Finally, are 
there other factors that can push the 
disease process resulting in TEN and 
SJS associated with viral infection?
The authors explained the differenc-
es between their results and the results 
of other investigators by (1) the larger 
number of MPR patient sera (n = 42) 
that was examined; (2) a rapid decline 
of sFasL levels during the first few days 
of disease onset, as we reported (Abe 
et al., 2003); and (3) that fact that the 
sFasL concentration in MPR patients 
seems to be dependent on the type 
of drug.
To further clarify whether sFasL 
levels are elevated in TEN and SJS, 
we have collected a number of TEN 
and SJS serum samples from a range 
of medical institutions in Japan. In 
fact, our data from more than 20 TEN 
patients indicate that high sFasL lev-
els were detected only in the early 
stage before mucosal lesions or bullae 
appeared (J.M. et al., manuscript in 
preparation).
What is the true mediator of apop-
tosis in TEN and SJS? Several papers 
have reported genetic factors related 
to drug hypersensitivity and the influ-
encing of drug metabolism and the 
immune response, including HLA 
genotypes. Chung et al. (2004) found 
that the alleles within the HLA region 
occurred at an increased frequency in 
patients with carbamazepine-induced 
SJS; particularly, HLA-B*1502 was 
present in 100% of carbamazepine-SJS 
patients but in only 3% of carbamaze-
pine-tolerant patients and in 8.6% of 
the general population. These findings 
could explain the rarity of TEN and SJS 
(approximately 100 cases per million 
per year). On the other hand, Fas and 
FasL polymorphisms might be asso-
ciated with an increased risk of par-
ticular diseases. A single-nucleotide 
polymorphism, identified at nucleo-
tide position –844C in the 5′ promoter 
of the FasL gene, and basal expression 
of FasL were also significantly higher 
in –844C than in –844T homozygous 
donors (Wu et al., 2003). The –844C 
homozygous genotype may lead to 
an increased expression of sFasL and 
alter FasL-mediated signaling in lym-
phocytes, enhancing the risk of auto-
immunity, such as in systemic lupus 
erythematosus (Wu et al., 2003). 
Furthermore, this single-nucleotide 
polymorphism confers host suscepti-
bility to cancers via enhanced activa-
tion-induced death of antigen-specific 
T cells (Sun et al., 2005). It is there-
fore possible that some genetic factors 
inducing susceptibility to Fas and FasL 
might influence the occurrence of TEN 
and SJS.
Another possibility is that suscep-
tibility to Fas/FasL may affect organ-
specific differences in apoptotic 
sensitivity. Previous reports have 
shown that acute-hepatitis patients 
have high sFasL concentrations in their 
sera (Shiota et al., 1998). We also have 
data indicating that high serum sFasL 
levels are detected in patients with 
drug-induced acute hepatitis (Murata, 
J. et al., unpublished data). We spec-
ulate that genetic backgrounds may 
influence organ-specific sensitivity of 
sFasL. Increases in sFasL expression 
may lead to development of TEN and 
SJS in patients with highly sFasL-sensi-
tive keratinocytes, whereas they may 
develop liver dysfunction in patients 
with high hepatocyte sFasL sensitivity.
An urgent review of pathophysiolo-
gy in TEN and SJS is needed to resolve 
this issue and to determine an effec-
tive treatment. Determining a single 
mediator in the pathogenesis of TEN 
and SJS may be difficult, because no 
single factor may explain the whole 
pathogenesis. The complicated rela-
tionship among soluble factors, cells, 
and their controlling genetic factors is 
likely to play a vital role in the patho-
genesis of TEN and SJS.
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